BAMCO Inc’s Edgewise Therapeutics EWTX Stock Holding History

BAMCO Inc’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-60,000	Closed	-$1.6M	–	321
2024 Q4	$1.6M	Buy	+60,000	New	+$1.91M	﹤0.01%	283

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BAMCO Inc's EWTX Position: Q1 2025 in Review

BAMCO Inc sold out of Edgewise Therapeutics (EWTX) in Q1 2025, closing a stake of 60,000 shares — an estimated $1.6M sold.

BAMCO Inc first reported a position in EWTX in Q4 2024 and held it in 1 quarter. The position peaked at $1.6M in Q4 2024. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

BAMCO Inc reported no remaining Edgewise Therapeutics position as of Q1 2025 after selling out during the quarter.
BAMCO Inc sold 60,000 Edgewise Therapeutics shares in Q1 2025, an estimated $1.6M.
BAMCO Inc first reported a position in Edgewise Therapeutics in Q4 2024 and held it in 1 quarter.
BAMCO Inc's Edgewise Therapeutics position peaked at $1.6M in Q4 2024.
192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on BAMCO Inc's 13F filing for Q1 2025, filed 15 May 2025.